Sector News

Takeda Announces Consolidation of U.S. Vaccine Sites in Boston/Cambridge Area

June 3, 2015
Life sciences
(BUSINESS WIRE) – Takeda Pharmaceutical Company Limited (“Takeda”) will consolidate its Vaccine Business Unit (VBU) operations by establishing global and regional hubs as the organization continues to grow and advance its important vaccine programs in norovirus, dengue and seasonal influenza.
 
The Boston/Cambridge, Massachusetts area, and Zurich, Switzerland will serve as VBU’s global hubs for the vaccine business outside of Japan. VBU will maintain regional hubs in Singapore and in Brazil and will operate manufacturing sites in Hikari, Japan; Durham, North Carolina and Singen, Germany.
 
In the U.S., all vaccine activities with the exception of manufacturing will move to the new global hub in the Boston/Cambridge area. This co-location will significantly enhance communication and collaboration across VBU’s divisions, and will allow VBU to leverage Takeda’s significant R&D presence in Cambridge. It will also provide access to the area’s remarkable biotech/pharmaceutical ecosystem and talent base.
 
Takeda will close its vaccine site in Bozeman, Montana, which it obtained through the acquisition of Ligocyte Pharmaceuticals in 2012, as well as the Madison, Wisconsin and Fort Collins, Colorado sites, which came to Takeda through the acquisition of Inviragen, Inc. in 2013. In addition, vaccine activities in Deerfield, Illinois, which currently serves as the global headquarters for VBU, will shift to the Boston/Cambridge area. This transition will occur in phases over the next two years, with the completion of U.S. consolidation by mid-2017.
 
“Takeda remains fully committed to the development of innovative vaccines that improve the lives of people around the world, including our norovirus, dengue and seasonal influenza candidate vaccines,” said Rajeev Venkayya, M.D., President, Takeda’s Vaccine Business Unit. “Our sites in Bozeman, Fort Collins, Madison and Deerfield have been instrumental in bringing our dengue and norovirus programs to late stages of clinical development. This consolidation will help us to achieve the efficiency and operational excellence needed to execute the Phase 3 clinical programs and set the stage for global commercialization of these vaccines.”
 
Source: Takeda Pharmaceutical Company Limited

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach